Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07593859 · ClinicalTrials.gov registry record · NA

Overcoming the Barriers to Effective Transcranial Temporal Interference Stimulation in Humans

A NA study, sponsored by Northeastern University.

Recruiting
Registry status
NA
Development phase
30
Enrollment target

NCT07593859: Recruiting NA study, sponsored by Northeastern University.

NCT07593859 is a NA study that is actively recruiting participants, run by Northeastern University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07593859, a NA study, is actively recruiting participants, sponsored by Northeastern University.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

Transcranial temporal interference stimulation (TIS) is an emerging novel tool for non-invasive transcranial brain stimulation that holds the potential for focal and steerable neuromodulation, and the possibility to stimulate focally at depth. TIS involves combining two high frequency waveforms to create a waveform with a "beat" frequency that is physiological relevant for neuromodulation. Successful applications to deep brain targets as well as steerability of the stimulation focus have been demonstrated in mice. Numerous recent investigations in humans have shown great clinical potential for this technology, however several questions about the basic mechanism of TIS action remain. The investigators will apply TIS to the motor cortex of humans and use established transcranial magnetic stimulation techniques to assess cortical excitability in relation to the phase of the TIS waveform. Using TMS, the investigators will i) validate that effects of TIS are due to the "beat" frequency and not the high frequency carrier signal, ii) evaluate the effect of the TIS carrier frequency, and iii) evaluate that whether changes in corticospinal excitability outlast the period of stimulation. Knowledge gained from this experiment will provide a basis for the future use of TIS for clinical applications, including informing parameter optimization.

Primary Outcome

Explained variance (R2) of best-fit sinusoids will be multiplied by the variance of measured values to obtain the established "relevance value" (R.V.), to be used as our primary outcome. Relevance values assume phase-dependent modulation with a large amplitude is more meaningful than one with small amplitude and the same R2. Critically, phase-dependent responses to TIS represent direct evidence of modulation at beat frequency (fb).

Interventions

  • DEVICE transcranial Temporal Interference Stimulation

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-02-01
Est. Completion 2029-10-01
Phase NA
Northeastern University

39 total trials

What NCT07593859 shows while recruiting

NCT07593859 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which transcranial Temporal Interference Stimulation is the first listed.

NCT07593859 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07593859 about?

NCT07593859 is a clinical study titled "Overcoming the Barriers to Effective Transcranial Temporal Interference Stimulation in Humans". Transcranial temporal interference stimulation (TIS) is an emerging novel tool for non-invasive transcranial brain stimulation that holds the potential for focal and steerable neuromodulation, and the possibility to stimulate focally at depth. TIS involves combining two high frequency waveforms to c...

What is the current status of trial NCT07593859?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-02-01. Estimated completion is 2029-10-01.

What interventions are being tested in trial NCT07593859?

The interventions under investigation include: transcranial Temporal Interference Stimulation (DEVICE).

Who is sponsoring clinical trial NCT07593859?

This trial is sponsored by Northeastern University, which has 39 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07593859's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07593859, the US trial registry maintained by the National Library of Medicine. NCT07593859 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.